Download PDF
Int J Angiol 2012; 21(02): 107-110
DOI: 10.1055/s-0032-1315622
Case Report
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Treatment of Late Class II Antibody-Mediated Rejection Status Postkidney Transplantation: Two Case Reports

Eric Siskind
1   North Shore Long Island Jewish Health System Transplantation Center, Manhasset, New York
,
Madhu Bhaskaran
1   North Shore Long Island Jewish Health System Transplantation Center, Manhasset, New York
,
Fouad Boctor
1   North Shore Long Island Jewish Health System Transplantation Center, Manhasset, New York
,
Kavin Shah
1   North Shore Long Island Jewish Health System Transplantation Center, Manhasset, New York
,
Ernesto Molmenti
1   North Shore Long Island Jewish Health System Transplantation Center, Manhasset, New York
› Author Affiliations
Further Information

Publication History

Publication Date:
28 May 2012 (online)

    Permissions and Reprints

Abstract

We are describing the successful treatment of two cases of late Class II antibody mediated rejection status postkidney transplantation. The first patient was treated with a combination of plasmapheresis, intravenous immunoglobulin (IVIG), and stenting of the transplanted renal artery. The second was treated with IVIG and pulse steroids.

Keywords

immune system - kidney - renal disease - stent - transplant - angioplasty - artery
 

  • References

  • 1 Sureshkumar KK, Oti IU, Baroody SC , et al. Treatment of antibody-mediated rejection after kidney transplantation. Transplant Proc 2008; 40 (5) 1373-1374
    CrossrefPubMedGoogle Scholar
  • 2 Rodríguez Ferrero M, Rincón A, Bucalo L, Rementería A, Anaya F. Treatment of acute antibody-mediated rejection: a single-center experience. Transplant Proc 2010; 42 (8) 2848-2850
    CrossrefPubMedGoogle Scholar
  • 3 Slatinska J, Honsova E, Burgelova M, Slavcev A, Viklicky O. Plasmapheresis and intravenous immunoglobulin in early antibody-mediated rejection of the renal allograft: a single-center experience. Ther Apher Dial 2009; 13 (2) 108-112
    CrossrefPubMedGoogle Scholar
  • 4 Lefaucheur C, Nochy D, Andrade J , et al. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9 (5) 1099-1107
    CrossrefPubMedGoogle Scholar
  • 5 Kaposztas Z, Podder H, Mauiyyedi S , et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 2009; 23 (1) 63-73
    CrossrefPubMedGoogle Scholar
  • 6 Lucas JG, Co JP, Nwaogwugwu UT, Dosani I, Sureshkumar KK. Antibody-mediated rejection in kidney transplantation: an update. Expert Opin Pharmacother 2011; 12 (4) 579-592 Review
    CrossrefPubMedGoogle Scholar
  • 7 Locke JE, Zachary AA, Haas M , et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 2007; 7 (4) 842-846
    CrossrefPubMedGoogle Scholar
  • 8 Nair R, Agrawal N, Lebaeau M, Tuteja S, Chandran PK, Suneja M. Late acute kidney transplant rejection: clinicopathological correlates and response to corticosteroid therapy. Transplant Proc 2009; 41 (10) 4150-4153 Erratum in Transplant Proc 2010;42(2):673
    CrossrefPubMedGoogle Scholar
  • 9 Hill GS, Nochy D, Loupy A. Accelerated arteriosclerosis: a form of transplant arteriopathy. Curr Opin Organ Transplant 2010; 15 (1) 11-15 Review
    CrossrefPubMedGoogle Scholar
  • 10 Takemoto SK, Zeevi A, Feng S , et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4 (7) 1033-1041
    CrossrefPubMedGoogle Scholar